📊 TOVX Key Takeaways
Is Theriva Biologics, Inc. (TOVX) a Good Investment?
Theriva Biologics is a pre-revenue stage biopharmaceutical company with a net loss of $25.2M and negative operating cash flow of $16.7M, indicating approximately 9-10 months of cash runway at current burn rates. With zero revenue, no approved commercial products, and ongoing substantial cash burn, the company faces critical liquidity risk and requires near-term clinical success or capital infusion for viability. The fundamental financial position is deteriorating with negative profitability metrics across all dimensions (ROE -164%, ROA -66%).
Why Buy Theriva Biologics, Inc. Stock? TOVX Key Strengths
- Conservative capital structure with Debt/Equity ratio of 0.11x
- Adequate short-term liquidity with Current Ratio of 1.74x
- Maintains $13.1M in cash reserves providing near-term operational capacity
TOVX Stock Risks: Theriva Biologics, Inc. Investment Risks
- Zero revenue with no commercialized products generating income
- Negative cash burn of $16.7M annually with only ~9-10 months of cash runway remaining
- Significant operating losses of $24.1M with no visible path to profitability
- Complete dependence on clinical trial success and external funding for survival
- Heavy cash consumption relative to asset base ($38.2M total assets)
Key Metrics to Watch
- Cash burn rate and remaining months of runway
- Clinical trial results and regulatory milestones
- Capital raising activities and new funding announcements
- Operating expense trends and cost management initiatives
Theriva Biologics, Inc. (TOVX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Theriva Biologics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
TOVX Profit Margin, ROE & Profitability Analysis
TOVX vs Healthcare Sector: How Theriva Biologics, Inc. Compares
How Theriva Biologics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Theriva Biologics, Inc. Stock Overvalued? TOVX Valuation Analysis 2026
Based on fundamental analysis, Theriva Biologics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Theriva Biologics, Inc. Balance Sheet: TOVX Debt, Cash & Liquidity
TOVX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Theriva Biologics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-19.03 indicates the company is currently unprofitable.
TOVX Revenue Growth, EPS Growth & YoY Performance
TOVX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2011 | $289.9K | -$732.8K | N/A |
| Q2 2011 | $355.6K | -$107.7K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Theriva Biologics, Inc. Dividends, Buybacks & Capital Allocation
TOVX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Theriva Biologics, Inc. (CIK: 0000894158)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TOVX
What is the AI rating for TOVX?
Theriva Biologics, Inc. (TOVX) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TOVX's key strengths?
Claude: Conservative capital structure with Debt/Equity ratio of 0.11x. Adequate short-term liquidity with Current Ratio of 1.74x.
What are the risks of investing in TOVX?
Claude: Zero revenue with no commercialized products generating income. Negative cash burn of $16.7M annually with only ~9-10 months of cash runway remaining.
What is TOVX's revenue and growth?
Theriva Biologics, Inc. reported revenue of $0.0.
Does TOVX pay dividends?
Theriva Biologics, Inc. does not currently pay dividends.
Where can I find TOVX SEC filings?
Official SEC filings for Theriva Biologics, Inc. (CIK: 0000894158) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TOVX's EPS?
Theriva Biologics, Inc. has a diluted EPS of $-2.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TOVX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Theriva Biologics, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TOVX stock overvalued or undervalued?
Valuation metrics for TOVX: ROE of -164.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TOVX stock in 2026?
Our dual AI analysis gives Theriva Biologics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TOVX's free cash flow?
Theriva Biologics, Inc.'s operating cash flow is $-16.7M, with capital expenditures of $35.0K.
How does TOVX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -164.1% (avg: 15%), current ratio 1.74 (avg: 2).